Tivozanib in renal cell carcinoma: a systematic review of the evidence and its dissemination in the scientific literature

BACKGROUND: Tivozanib (Fotivda) is an anti-angiogenic tyrosine kinase inhibitor that was denied access to the US market by the Food and Drug Administration (FDA). In contrast, it was granted approval by the European Medicines Agency (EMA) for the treatment of Renal Cell Carcinoma in adults. Given th...

Descripción completa

Detalles Bibliográficos
Autores principales: Caquelin, Laura, Gewily, Mohamed, Mottais, Wendy, Tebaldi, Chloé, Laviolle, Bruno, Naudet, Florian, Locher, Clara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994226/
https://www.ncbi.nlm.nih.gov/pubmed/35397511
http://dx.doi.org/10.1186/s12885-022-09475-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994226/
https://www.ncbi.nlm.nih.gov/pubmed/35397511
http://dx.doi.org/10.1186/s12885-022-09475-7

Ejemplares similares